All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MDS content recommended for you
ASH 2022
27 May 2023
Promising outcomes of novel treatments (sabatolimab, imetelstat, and canakinumab) in patients with MDS were presented at the oral abstract session of #ASH22. Check out our summary here 👉 https://t.co/UXYfqS0wWb.
#mdssm
3 Mar 2023
Check out our summary here 👉 https://t.co/UXYfqS0wWb. #mdssm
6 Feb 2023
👉 https://t.co/jkVX37wn7V. #Lymsm
14 Dec 2022
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #mdssm
13 Dec 2022
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…
13 Dec 2022
@bhwords of @GSTTnhs discusses the how COVID-19 has brought unforeseen challenges to the thrombosis comm…
13 Dec 2022
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory pos…
13 Dec 2022
Saverio D’Amico, @HumanitasMilano, explained that development of a federated learning algorithm allows for clinical implementation.
#mdssm #medicalcongress
13 Dec 2022
Saverio D’Amico, of @HumanitasMilano, presented a machine/deep learning learning approach for prognostic assessment and classification in MN. Survival prediction models were compared across 2043 patients with MDS.
#mdssm #medicalcongress
12 Dec 2022
12 Dec 2022
Guillermo Garcia-Manero discussed a phase II trial of canakinumab in pts with lower-risk #MDS. Canakinumab was found to decrease the frequencies of HSCs and MPPs. Canakinumab was safe and there were no severe AEs.
#MDSsm #medicalcongress
12 Dec 2022
The @MDS_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Sessions covered today:
637 and poster sessions
#hematology #medicalcongress #cancerresearch #mdssm
12 Dec 2022
Amer Zeidan @Dr_AmerZeidan reports severe neutropenia/agranulocytosis = 3.5% in the registry, and 13.3% in the CPU, but highlights limitations of non-randomized, uncontrolled real-world studies. #mmsm
12 Dec 2022
Amer Zeidan @Dr_AmerZeidan of @Yale explains that no new or unexpected AEs were seen in patients with MDS treated with the oral iron chelator deferiprone in a US safety registry (n = 115) and compassionate use program (CPU) (n = 15).
#mdssm
11 Dec 2022
Naval Daver @Daver_Leukemia, @MDAndersonNews presented phase Ib/II trial of pivekimab sunirine (PVEK)+Aza+Ven triplet in R/R AML. In 91 patients, ORR = 45% and composite CR = 25% (duration 7.7 months), with a manageable safety profile. #leusm
11 Dec 2022
Maria Diez-Campelo @madicamp @IBSAL_IIS describes low dose lenalidomide in anemic non-transfusion-dependent low risk MDS del(5q) (n = 61) delayed and decreased transfusion dependency (25%) vs placebo (65%) in the phase III Sintra-REV trial.
#mdssm
11 Dec 2022
Uwe Platzbecker @UwePlatzbecker reports that of 38 patients with non-del(5q) and no prior lenalidomide/HMA treatment, 11 (29%) achieved TI ≥1 year. Median TI duration = 92.4 weeks, PFS = 34.2 & OS = 56.1 months.
#mdssm
11 Dec 2022
Uwe Platzbecker @UwePlatzbecker, @UniLeipzig, presents phase II data from IMerge trial of the first-in-class telomerase inhibitor imetelstat in RBC transfusion-dependent and erythropoiesis stimulating agent R/R lower-risk MDS.
#mdssm
11 Dec 2022
11 Dec 2022
11 Dec 2022
11 Dec 2022
11 Dec 2022
The @MDS_Hub will be covering the following session(s) today:
617 and 637
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #hematology #medicalcongress #cancerresearch #mdssm
11 Dec 2022
10 Dec 2022
10 Dec 2022
10 Dec 2022
6 Dec 2022
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @MDS_hub!
📌Find out more: https://t.co/9EsQhePRL6
#ASH2022 #mdssm #medicalabstracts #cancer
30 Nov 2022
To help navigate the exciting sessions, check out our top abstract list to see what’s hot in #MDS 👉 https://t.co/9EsQhePRL6. #MDSsm #leusm #medicalcongress
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content